share_log

DEF 14A: Definitive information statements

DEF 14A: Definitive information statements

DEF 14A：股東委託書決議
美股sec公告 ·  05/03 20:05
牛牛AI助理已提取核心訊息
SeaStar Medical Holding Corporation (SeaStar Medical) has announced the filing of a definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission (SEC) for its 2024 Annual Meeting of Stockholders. The meeting is scheduled for June 4, 2024, at 10:00 a.m. Mountain Time and will be held virtually. The proxy statement details the matters to be presented at the meeting, including the election of three Class II Directors, the approval of an amendment to the company's 2022 Omnibus Equity Incentive Plan to increase authorized shares, the approval of the issuance of 20% or more of the company's outstanding shares of Common Stock upon exercise of Series A and Series B Warrants, and the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The notice also includes instructions for stockholders on how to vote and attend the meeting online. Eric Schlorff, Director and CEO of SeaStar Medical, has urged stockholders to vote promptly, highlighting the importance of their votes being represented.
SeaStar Medical Holding Corporation (SeaStar Medical) has announced the filing of a definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission (SEC) for its 2024 Annual Meeting of Stockholders. The meeting is scheduled for June 4, 2024, at 10:00 a.m. Mountain Time and will be held virtually. The proxy statement details the matters to be presented at the meeting, including the election of three Class II Directors, the approval of an amendment to the company's 2022 Omnibus Equity Incentive Plan to increase authorized shares, the approval of the issuance of 20% or more of the company's outstanding shares of Common Stock upon exercise of Series A and Series B Warrants, and the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The notice also includes instructions for stockholders on how to vote and attend the meeting online. Eric Schlorff, Director and CEO of SeaStar Medical, has urged stockholders to vote promptly, highlighting the importance of their votes being represented.
海星醫療控股公司（SeaStar Medical）宣佈向美國證券交易委員會（SEC）提交其2024年年度股東大會的最終委託書（DEF 14A）。會議定於山區時間2024年6月4日上午10點舉行，將以虛擬方式舉行。委託書詳細說明了將在會議上提出的事項，包括選舉三名二類董事，批准公司2022年綜合股權激勵計劃的修正案，以增加法定股份，批准在行使A系列和B系列認股權證時發行公司20％或以上的已發行普通股，以及批准WithumSmith+Brown, PC 作爲截至12月的財政年度的獨立註冊會計師事務所 2024 年 31 日。該通知還包括股東如何在線投票和參加會議的說明。SeaStar Medical董事兼首席執行官埃裏克·施洛夫敦促股東迅速投票，強調了代表他們的選票的重要性。
海星醫療控股公司（SeaStar Medical）宣佈向美國證券交易委員會（SEC）提交其2024年年度股東大會的最終委託書（DEF 14A）。會議定於山區時間2024年6月4日上午10點舉行，將以虛擬方式舉行。委託書詳細說明了將在會議上提出的事項，包括選舉三名二類董事，批准公司2022年綜合股權激勵計劃的修正案，以增加法定股份，批准在行使A系列和B系列認股權證時發行公司20％或以上的已發行普通股，以及批准WithumSmith+Brown, PC 作爲截至12月的財政年度的獨立註冊會計師事務所 2024 年 31 日。該通知還包括股東如何在線投票和參加會議的說明。SeaStar Medical董事兼首席執行官埃裏克·施洛夫敦促股東迅速投票，強調了代表他們的選票的重要性。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。